Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes

April 2011
Diabetes Care;Apr2011, Vol. 34 Issue 4, p789
Academic Journal
The article examines the benefits and safety of time-release bromocriptine (Cycloset), a sympatholytic dopamine D&sub2; receptor agonist, for the treatment of type 2 diabetes. According to the author, bromocriptine is considered because its effects are mediated through a resetting of dopaminergin and sympathetic tone within the central nervous system (CNS). The drug, after ingestion, dissolves and is absorbed rapidly within 30 minutes. Its quick release offer peak concentrations within 60 minutes. Common side effects include nausea and constipation.


Related Articles

  • Bromocriptine for Type 2 Diabetes. Kuritzky, Louis // Neurology Alert;Jun2011 Clinical Brief, p12 

    The article presents a report by R. A. DeFronzon published in the "Diabetes Care" journal that informed that Bromocriptine is a new and novel treatment for type 2 diabetes (DM2).

  • Bromocriptine for Type 2 Diabetes. Kuritzky, Louis // Infectious Disease Alert;Jun2011 Clinical Briefs in Primary, p12 

    The article discusses research by R. A. DeFronzo on the efficiency of bromocriptine for the treatment of type 2 diabetes, published in a 2011 issue of "Diabetes Care."

  • Bromocriptine for Type 2 Diabetes.  // OB/GYN Clinical Alert;Jun2011 Clinical Brief, p12 

    The article provides a discussion about bromocriptine (BRO) as a novel treatment for type 2 diabetes (DM2) in which it will reset the levels of dopaminergic and sympathetic tone within the central nervous system (CNS).

  • New formulation of bromocriptine for diabetes. Taylor, James R. // Endocrine Today;Apr2011, Vol. 9 Issue 4, p33 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of quick-release bromocriptine as a new formulation for the treatment of type 2 diabetes.

  • Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial. Ghosh, Arijit; Sengupta, Nilanjan; Sahana, Pranab; Giri, Debasis; Sengupta, Parama; Das, Nina // Indian Journal of Pharmacology;Jan/Feb2014, Vol. 46 Issue 1, p24 

    Objective: To compare the effectiveness and safety of add on therapy of bromocriptine with metformin in type 2 diabetes mellitus (DM) patients. Material and Methods: Adult type 2 DM patients fulfilling the inclusion criteria were randomized in three groups. Group A received metformin (1000 mg/...

  • Development of a Rapid Insulin Assay by Homogenous Time-Resolved Fluorescence. Farino, Zachary J.; Morgenstern, Travis J.; Vallaghe, Julie; Gregor, Nathalie; Donthamsetti, Prashant; Harris, Paul E.; Pierre, Nicolas; Freyberg, Robin; Charrier-Savournin, Fabienne; Javitch, Jonathan A.; Freyberg, Zachary // PLoS ONE;2/5/2016, Vol. 11 Issue 2, p1 

    Direct measurement of insulin is critical for basic and clinical studies of insulin secretion. However, current methods are expensive and time-consuming. We developed an insulin assay based on homogenous time-resolved fluorescence that is significantly more rapid and cost-effective than current...

  • Exenatide Injection (Byetta): Adjunctive Therapy for Glycemic Control. Ezzo, Danielle C.; Ambizas, Emily M. // American Family Physician;6/15/2006, Vol. 73 Issue 12, p2213 

    The article focuses on the administration of exanatide as an adjunctive therapy for glycemic control in patients with type 2 diabetes. Exenatide is an incretin mimetic which enhances glucose-dependent insulin secretion by the pancreatic beta cells. Exenatide injection is not a substitute for...

  • Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association's 72nd Scientific Sessions.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that the American Diabetes Association which was held in Philadelphia, Pennsylvania featured a presentation on LGD-6972 by Ligand Pharmaceuticals Inc. It mentions that the clinical trial of LGD-6972 yielded positive results for the treatment of type 2 diabetes. It further...

  • Pharmacological Management of Type 2 Diabetes Mellitus: An Update. El-Kaissi, Samer; Sherbeeni, Suphia // Current Diabetes Reviews;Nov2011, Vol. 7 Issue 6, p392 

    While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics